Regeneron Pharmaceuticals Stock News

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals. Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.

A recent legal ruling raises an important question about Intellia Therapeutics' path forward.

The WHO panel is also evaluating data for Pfizer's antiviral pill, paxlovid, and a widely available antidepressant, fluvoxamine, to treat Covid-19.

The World Health Organization in its updated guidelines recommended Regeneron Pharmaceuticals'' (REGN) COVID-19 antibody cocktail REGEN-COV (casirivimab- imdevimab) only for people who…

Regeneron Pharmaceuticals Inc on Wednesday failed to persuade a federal judge in New York to throw out a lawsuit over its alleged misuse of a patented protein to test its breakthrough COVID-19 treatment.

Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine, Inc. (NASDAQ: EDIT) sai

On Monday, Intellia Therapeutics (NTLA) and Regeneron Pharmaceuticals (REGN) issued updated interim data for CRISPR gene editing candidate NTLA-2001 from a Phase 1 trial in…

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The interim data released today include 15 hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients treated across four single-ascending dose cohorts. Single doses of 0.1 mg/kg, 0.3 mg/kg, 0.7 mg/kg, and 1.0 mg/kg of NTLA-2001 were administered via intravenous infusion and changes from baseline values of serum transthyretin (TTR) protein were measured for each patient. Treatment with NTLA-2001 led to dose-dependent reductions in serum TTR and achieved maximal reductions by day 28, with mean reductions of 52%, 87%, and 86% among the three patients each in the 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg dose groups, respectively, and 93% among the six patients in the 1.

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Topline wet AMD data was released and KSI-301 failed to show non-inferiority against standard of care treatment. Click here to see what it means for Kodiak Sciences.

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

A great way to find low volatility stocks is to look for a beta that's less than 1.0. Here are seven to buy as market turbulence increases.

A disappointing clinical trial result is weighing heavily on the drugmaker's shares today.

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.